arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Relay Therapeutics, Inc.

RLAY
$19.79 ▲ +0.08 (+0.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
30 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Relay Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.6B
Dividend Yield
Revenue Growth -60.9%
Op. Margin None
ROIC -9.7%
FCF / Share $-0.28
Trailing P/E
Price / Book 5.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.00M
↓ -60.9%
Net Income Profit after all expenses
$-73.29M
↑ +4.9%
FCF / Share Free cash flow per share
$-0.28
↑ +34.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters